Hillsdale Investment Management Inc. Boosts Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Posted by on Jul 15th, 2026

Hillsdale Investment Management Inc. boosted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 14.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 639,100 shares of the biotechnology company’s stock after acquiring an additional 80,000 shares during the quarter. Hillsdale Investment Management Inc. owned about 0.25% of BioCryst Pharmaceuticals worth $6,084,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of BCRX. Phocas Financial Corp. purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $1,956,000. Aberdeen Group plc acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $7,126,000. Vanguard Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after buying an additional 482,494 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in BioCryst Pharmaceuticals by 21.4% during the fourth quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock worth $19,833,000 after acquiring an additional 448,436 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in BioCryst Pharmaceuticals by 106.5% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock worth $1,820,000 after acquiring an additional 120,350 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Down 1.7%

BioCryst Pharmaceuticals stock opened at $9.74 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.22. The firm’s 50-day simple moving average is $9.17 and its 200 day simple moving average is $8.48. The firm has a market capitalization of $2.48 billion, a PE ratio of -5.47 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of recent analyst reports. Needham & Company LLC reduced their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wedbush reduced their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Cantor Fitzgerald boosted their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

View Our Latest Report on BCRX

About BioCryst Pharmaceuticals

(Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Featured Stories

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.